Skip to NavigationSkip to content

Genentech to axe 223 staff from San Francisco HQ

Published on 17/08/18 at 10:09am

Roche subsidiary Genentech has announced plans to axe 223 employees from its headquarters in San Francisco, California, beginning on 31 August and running on into November.

The company’s decision was confirmed in a Worker Adjustment and Retraining Notification (WARN) letter posted by the State of California’s Employment Development Department.

“We have been evaluating some of our operations to ensure we remain well-positioned to meet the needs of patients today and deliver on our pipeline of new medicines in the future,” the company relayed in a statement. “As a result of this process, we have made the difficult decision to eliminate some positions.”

The move is thought to be in part a response to the incoming competition that its parent company Roche anticipates from biosimilars against its top-selling cancer drugs Rituxan (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), which together generated over $20 billion for the company in 2017.

Genentech announced similar plans to cut 130 staff at a California site and 235 at a European facility late last year.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches